B

Biotel

Description

Biotel

Investor Profile

Biotel has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B rounds (top funding stages).
  • Majority of deals are located in Israel.
  • Strong thematic focus on Biotechnology, Pharmaceutical, Health Care.

Stage Focus

  • Series C (50%)
  • Series B (50%)

Country Focus

  • Israel (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Therapeutics
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Biotel frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 1
Integra Holdings
Europe, Zurich, Switzerland, Wallisellen
Co-Investments: 1
Israel Biotech Fund
Asia, HaMerkaz, Israel, Rehovot
Co-Investments: 2
Migdal Insurance and Financial Holdings
Asia, HaMerkaz, Israel, Petah Tikwah
Co-Investments: 1
AB
Asia, Tel Aviv, Israel, Herzliya
Co-Investments: 1
Cystic Fibrosis Foundation
North America, Maryland, United States, Bethesda
Co-Investments: 1
Phoenix Financial
Asia, Tel Aviv, Israel, Tel Aviv
Co-Investments: 1
Primera Capital
North America, California, United States, Oakland
Co-Investments: 1

What are some of recent deals done by Biotel?

Splisense

Jerusalem, Yerushalayim, Israel

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.

BiotechnologyLife SciencePharmaceutical
Series BMay 13, 2021
Amount Raised: $28,500,000
BioSight

Carmiel, HaZafon, Israel

Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series CDec 2, 2020
Amount Raised: $27,000,000